PMID- 37843353
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 27
IP  - 19
DP  - 2023 Oct
TI  - Compliance level to Tuberculosis prophylaxis in patients undergoing therapy with 
      tumor necrosis factor-alpha inhibitors: a cross-sectional study.
PG  - 9413-9419
LID - 33969 [pii]
LID - 10.26355/eurrev_202310_33969 [doi]
AB  - OBJECTIVE: Tumor necrosis factor-alpha (TNF-alpha) inhibitors are used to treat 
      autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, and 
      inflammatory bowel disease. However, patients using TNF-alpha inhibitors are at a 
      high risk of developing tuberculosis. Therefore, this study aimed to evaluate the 
      compliance level of patients who were prescribed TNF-alpha-based tuberculosis 
      prophylactic treatment. PATIENTS AND METHODS: The study included 135 patients who 
      were followed up at a tuberculosis dispensary between December 2020 and June 2021 
      and agreed to participate in the study. The study was conducted after obtaining 
      necessary permissions from the institution, ethics committee, and patients. Data 
      were collected using a questionnaire and evaluated using the Medication Adherence 
      Report Scale (MARS). The MARS scale scores range from 5 to 25, with high scores 
      indicating a high level of "medication compliance level". RESULTS: Of the 
      included patients, 42.2% were females, 46.7% were primary school graduates, and 
      their mean age was 43.75+/-11.86 years. Additionally, 35.6% of patients had 
      ankylosing spondylitis, among whom 54.1% had a disease duration of 1-5 years and 
      57.8% had been using TNF-alpha inhibitors for a year. Of the patients taking 
      isoniazid (INH) for tuberculosis prophylaxis, 47.4% missed their prescribed INH 
      doses, with "forgetfulness" being the reason in 28.9% of these patients. The 
      patients had a mean MARS score of 15.71+/-6.18. CONCLUSIONS: Patients using TNF-alpha 
      inhibitors were found to have "moderate" compliance levels for INH-based 
      prophylactic therapy. It is recommended that the compliance levels of patients 
      and factors influencing their compliance should be regularly monitored.
FAU - Aytac, S
AU  - Aytac S
AD  - Department of Nursing, Faculty of Health Sciences, Gaziantep University, 
      Gaziantep, Turkey. aytac.sema27@gmail.com.
FAU - Ovayolu, O
AU  - Ovayolu O
FAU - Dogru, S
AU  - Dogru S
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - V83O1VOZ8L (Isoniazid)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Female
MH  - Humans
MH  - Adult
MH  - Middle Aged
MH  - Male
MH  - Tumor Necrosis Factor-alpha/therapeutic use
MH  - *Spondylitis, Ankylosing/drug therapy
MH  - Cross-Sectional Studies
MH  - *Tuberculosis/drug therapy/prevention & control
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - Isoniazid/therapeutic use
MH  - Immunologic Factors/therapeutic use
EDAT- 2023/10/16 12:42
MHDA- 2023/11/02 12:44
CRDT- 2023/10/16 09:13
PHST- 2023/11/02 12:44 [medline]
PHST- 2023/10/16 12:42 [pubmed]
PHST- 2023/10/16 09:13 [entrez]
AID - 33969 [pii]
AID - 10.26355/eurrev_202310_33969 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2023 Oct;27(19):9413-9419. doi: 
      10.26355/eurrev_202310_33969.